Luke Evnin, PhD
Dr. Evnin is the chairman of the board and a co-founder of Harpoon Therapeutics; he is also the co-founder and managing director of MPM Capital. MPM Capital is known for its leadership role in building companies such as Biomarin, CoStim Pharmaceuticals (acquired by Novartis), Epizyme, Idenix (acquired by Merck) Pacira, Pharmasset (acquired by Gilead) and Radius. Dr. Evnin was the lead investor and has served on the boards of several of MPM’s most successful investments including CoStim Pharmaceuticals, Idun Pharmaceuticals, and Pacira. Prior to MPM, Dr. Evnin was a venture capitalist at Accel Partners where he focused on emerging healthcare companies. He received his AB in molecular biology from Princeton University and received his PhD in Biochemistry from the University of California, San Francisco. He is the chairman of the Scleroderma Research Foundation, as well as an advisor for the Lewis-Sigler Institute for Quantitative Genomics at Princeton, for QB3 at UCSF, and for Mission Bay Capital at UCSF.
Patrick Baeuerle, PhD
Dr. Baeuerle is co-founder of Harpoon and remains a key consultant for the company. He is an executive partner of MPM Capital and has co-founded MPM companies TCR2, iOmx, and Maverick Therapeutics. Prior to joining MPM, Dr. Baeuerle oversaw the development of T-cell engaging antibody Blincyto® (blinatumomab), and spearheaded the development of the BiTE platform as chief scientific officer for Micromet, Inc., and as vice president, research, for Amgen. He served as professor and chairman of biochemistry at Freiburg University, Germany, and is an honorary professor of immunology of the Medical Faculty at Munich University.
Pablo Cagnoni, MD
Dr. Cagnoni is the president and chief executive officer of MPM portfolio company Tizona Therapeutics and executive chair of Blade Therapeutics. As an oncologist and pharmaceutical executive, he has played a key role in the development, approval and/or commercialization of several life-changing medicines, including Afinitor®, Blincyto®, Exjade®, Folotyn® Glivec®, Jakavi®, Kyprolis®, Signifor®, Tarceva®, Tasigna® and Zykadia® among them. Most recently, he served as president of Onyx Pharmaceuticals where he had global strategic oversight of the Onyx portfolio from early product development to commercialization. Previously, he was senior vice president and global head of clinical development at Novartis Oncology. Dr. Cagnoni was also senior vice president and chief medical officer at Allos Therapeutics (acquired by Spectrum Pharmaceuticals) and, prior to that, chief medical officer of OSI Pharmaceuticals (acquired by Astellas). Dr. Cagnoni earned his medical degree from University Buenos Aires School of Medicine, and completed a fellowship in hematology and oncology in Mount Sinai Medical Center, New York and a fellowship in stem cell transplantation at the University of Colorado Health Sciences Center.
Mark Chin, MS, MBA
Mark Chin, investment manager at Arix Bioscience, currently sits on the board of Iterum Therapeutics, Harpoon Therapeutics and OptiKira. He was previously a principal at Longitude Capital, where he focused on investments in both private and public biotechnology and medical technology companies. Prior to Longitude, Chin was a consultant at the Boston Consulting Group, where he was responsible for strategy and corporate development projects for pharmaceutical and biotechnology companies. Before BCG, he worked in corporate development at Gilead Sciences and market planning at Genentech. Chin has an MBA from The Wharton School at the University of Pennsylvania, an MS in Biotechnology from the University of Pennsylvania, and a BS in Management Science from the University of California at San Diego.
Dan Hicklin, PhD
Dr. Hicklin joined MPM in 2014 subsequent to his successful role as president, chief scientific officer and member of the board of CoStim Pharmaceuticals (acquired by Novartis). He now serves as president and CEO of Potenza Therapeutics, an immuno-oncology company founded by MPM. In addition to Harpoon, he is also a board member of Tizona Therapeutics, another MPM portfolio company. Prior to CoStim, Dr. Hicklin led the biologics strategy for the oncology and immuno-modulation discovery teams at Merck Research Laboratories and oversaw numerous immuno-oncology discovery and development projects. Dr. Hicklin also served as vice president of experimental therapeutics at ImClone Systems (acquired by Eli Lilly), where his team supported the development and FDA approval of the cancer treatment Erbitux® (cetuximab) and built a diversified portfolio of antibody therapeutics including Cyramza® (ramucirumab), Portrazza® (necitumumab) and other novel agents. Dr. Hicklin received his Master’s degree and PhD in immunology from New York Medical College, and his BS from the University of Iowa.
Ron Hunt, MBA
Ron Hunt is a managing director at New Leaf Venture Partners, and focuses on investments in biopharmaceutical companies. Hunt was one of the founders of New Leaf following the spin out from the Sprout Group in 2005, and has nearly two decades of venture capital investment experience. Hunt has played a significant role in many of the firm’s investments in biopharmaceuticals and in other sectors. He currently on the boards of Iterum Therapeutics, Karos Pharmaceuticals, and Neuronetics, Inc. Hunt is a graduate of The Wharton School (MBA) and Cornell University (BS).
Gerald McMahon, PhD
Dr. McMahon joined Harpoon in December 2016 bringing more than 25 years of biotechnology leadership, scientific innovation and creative deal-making experience. Dr. McMahon was previously president and CEO of Kolltan Pharmaceuticals, an oncology biologics company acquired by Celldex in 2016, and senior vice president of R&D oncology at MedImmune, the biologics arm of AstraZeneca. He also served as a venture partner at Bay City Capital and in executive leadership roles at Poniard Pharmaceuticals and SUGEN (ultimately acquired by Pfizer), where he was a key player in the development of innovative oncology drugs Sutent® and Palladia®.
Dr. McMahon holds an academic appointment at the Yale Comprehensive Cancer Center at Yale University, and held previous appointments at Tufts University School of Medicine, department of hematology & oncology at the New England Medical Center, and the Massachusetts Institute of Technology. He received his BS in biology and PhD in biochemistry from Rensselaer Polytechnic Institute.